GSC
GLMD icon

Ground Swell Capital’s Galmed Pharmaceuticals GLMD Stock Holding History

Ground Swell Capital’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-58
Closed -$5.18K – 74
2022
Q4 		$5.18K Sell
58
-14
-19% -$917 0.02% 75
2022
Q3 		$4K Buy
+72
New +$6.14K 0.01% 95
2014
Q3 		$1K Hold
1
– – ﹤0.01% 2130
2014
Q2 		$2K Buy
+1
New +$1.53K ﹤0.01% 1487

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ground Swell Capital's GLMD Position: Q1 2023 in Review

Ground Swell Capital sold out of Galmed Pharmaceuticals (GLMD) in Q1 2023, closing a stake of 58 shares — an estimated $5.18K sold.

Ground Swell Capital first reported a position in GLMD in Q2 2014 and held it in 4 quarters. The position peaked at $5.18K in Q4 2022. 20 funds tracked by Wall St. Rank hold GLMD as of Q1 2023.

  • Ground Swell Capital reported no remaining Galmed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Ground Swell Capital sold 58 Galmed Pharmaceuticals shares in Q1 2023, an estimated $5.18K.
  • Ground Swell Capital first reported a position in Galmed Pharmaceuticals in Q2 2014 and held it in 4 quarters.
  • Ground Swell Capital's Galmed Pharmaceuticals position peaked at $5.18K in Q4 2022.
  • 20 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2023.

Based on Ground Swell Capital's 13F filing for Q1 2023, filed 8 May 2023.